Mark Ragosa

Senior Vice President and Chief Financial OfficeratKiniksa Pharmaceuticals International· In proxies 2022–2025

Pay in FY2025+49% from the year before · Kiniksa Pharmaceuticals International stock +108.5% the same year

Mark Ragosa was paid $3.3M in FY2025 (Dec), up 49%. Kiniksa Pharmaceuticals International stock rose 108.5% that year.

Pay$100 in the stock at the end of FY21 → $350

Pay is from the Summary Compensation Table of each Kiniksa Pharmaceuticals International proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

KNSA
Kiniksa Pharmaceuticals InternationalPublic company · 4 yr
- Senior Vice President and Chief Financial Officer2022 – Present · 4 yrStock in role +662%

Roles come from the proxy statements of each company.

Activity

Pay
Kiniksa Pharmaceuticals International CFO pay rose 49% to $3.3M. The stock rose 109% in FY2025 (Dec).
DEF 14AApr 16, 2026
Pay
Kiniksa Pharmaceuticals International CFO pay rose 25% to $2.2M. The stock rose 13% in FY2024 (Dec).
DEF 14AApr 21, 2025

For the press:Download CSV Download PNG How to use our data

Two people shown as one, or a wrong number?